Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STM-01 in HFpEF
NCT06560762Phase 1Recruiting
- Sponsor
- Secretome Therapeutics
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Lipid-based Nanoparticles, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of STM-01 in heart failure with preserved ejection fraction (HFpEF) (2 cohorts), sponsored by Secretome Therapeutics. Primary endpoint: Frequency, grade and relationship to STM-01 of unsolicited local and systemic AEs at Day 56. Started Mar 2025; status: recruiting.
02
Drugs
STM-01
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06560762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560762.